Fulgent Genetics Cash Flow Statement
NASDAQ: FLGTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Fulgent Genetics free cash flow
In fiscal 2025, Fulgent Genetics generated -$101.6 million of operating cash flow and spent $22.6 million on capital expenditures. That left free cash flow of -$124.2 million, a free-cash-flow margin of -38.5% of revenue. Fulgent Genetics returned $10.9 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Fulgent Genetics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -61.63M | -43.82M | -175.24M | 141.92M | 506.24M | 214.31M | -411.00K | -5.61M | -2.51M | -5.35M |
| Net Income growth (YoY) | — | — | -223.47% | -71.97% | +136.22% | — | — | — | — | — |
| Depreciation & Amortization | 24.12M | 24.93M | 26.14M | 32.66M | 11.00M | 2.96M | 2.11M | 2.16M | 1.73M | 1.17M |
| Stock-Based Compensation | 39.58M | 44.48M | 42.92M | 32.64M | 15.88M | 8.16M | 3.21M | 2.30M | 2.12M | 4.65M |
| Change in Working Capital | -20.50M | -13.68M | -8.16M | 41.18M | 37.90M | -177.01M | -794.00K | -1.24M | 949.00K | -1.60M |
| Operating Cash Flow | -101.64M | 21.06M | 27.00M | 253.52M | 538.58M | 140.63M | 5.52M | -675.00K | 1.33M | 4.41M |
| Capital Expenditures | -22.57M | -40.31M | -22.21M | -18.77M | -23.81M | -35.13M | -1.18M | -2.32M | -2.90M | -3.79M |
| Investing Cash Flow | 111.37M | -58.35M | 38.90M | -261.31M | -546.55M | -326.44M | -29.05M | 950.00K | -2.05M | -42.80M |
| Share Repurchases | -10.88M | -225.00K | -25.06M | -74.34M | — | -62.00K | -21.00K | — | — | -11.98M |
| Debt Issued | — | — | — | — | — | 15.02M | — | — | — | — |
| Debt Repaid | — | — | -15.00M | — | — | — | — | — | — | — |
| Financing Cash Flow | -14.79M | -4.85M | -47.78M | -77.14M | 85.41M | 261.25M | 28.77M | 15.00K | -770.00K | 45.79M |
| Net Change in Cash | -4.95M | -42.19M | 17.97M | -85.39M | 77.47M | 75.46M | 5.23M | 246.00K | -1.41M | 7.40M |
| Free Cash Flow | -124.21M | -19.25M | 4.80M | 234.75M | 514.76M | 105.50M | 4.33M | -3.00M | -1.56M | 617.00K |
This table shows 10 annual periods of Fulgent Genetics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow FLGT's reporting calendar. What is a cash flow statement?